吉非替尼一线治疗非小细胞肺癌脑膜转移12例分析  

Meningeal carcinomatosis treated by gefitinib as first-line therapy for non-small cell lung cancer:a 12 cases report

作　　者：李相勇[1] 范晓强[1] 周仁贵[1] 唐新宇[1] 潘德键[1] 许亚凤[1] 周锡建[1] 

机构地区：[1]解放军第101医院血液肿瘤科,江苏无锡214044

出　　处：《临床肿瘤学杂志》2010年第10期922-924,共3页Chinese Clinical Oncology

摘　　要：目的观察吉非替尼作为非小细胞肺癌（NSCLC）脑膜转移一线治疗方案的疗效和不良反应。方法 12例NSCLC脑膜转移患者服用吉非替尼250mg,1/日,直至疾病进展。结果 12例患者获CR8.3%,PR41.7%,DCR75.0%,中位总生存期10.2个月,中位无进展生存期7.8个月。药物引起的毒副反应大部分为1~2级,未因不良反应而减停。结论吉非替尼一线用于NSCLC脑膜转移安全有效,值得进一步研究。Objective To evaluate the efficacy and toxicity of gefitinib as the first-line therapy for non-small cell lung cancer（NSCLC） patients with meningeal carcinomatosis.Methods Totally,12 patients were enrolled and given gefitinib 250mg per day untill disease progressed.Results For all enrolled patients,CR was 8.3%,PR 41.7%,DCR 75.0%,median OS 10.2 months,and median PFS 7.8months.Most drug-related adverse events were mild and tolerable.No patients received reduced dosage or discontinued treatment because of side effects.Conclusion Gefitinib is effective and safe in patients with meningeal carcinomatosis from NSCLC and worth further study.

关 键 词：吉非替尼 脑膜癌病 非小细胞肺癌 

分 类 号：R730.6[医药卫生—肿瘤]